Next Article in Journal
Two-Tiered Newborn Screening with Post-Analytical Tools for Pompe Disease and Mucopolysaccharidosis Type I Results in Performance Improvement and Future Direction
Previous Article in Journal
Family Perspectives on Newborn Screening for X-Linked Adrenoleukodystrophy in California
Open AccessReview

Is Newborn Screening the Ultimate Strategy to Reduce Diagnostic Delays in Pompe Disease? The Parent and Patient Perspective

Australian Pompe Association Inc., Kellyville, NSW 2155, Australia
*
Author to whom correspondence should be addressed.
Int. J. Neonatal Screen. 2020, 6(1), 1; https://doi.org/10.3390/ijns6010001
Received: 18 December 2019 / Revised: 2 January 2020 / Accepted: 6 January 2020 / Published: 9 January 2020
(This article belongs to the Special Issue Newborn Screening for Pompe Disease)
Pompe disease (PD) is a rare, autosomal-recessively inherited deficiency in the enzyme acid α-glucosidase. It is a spectrum disorder; age at symptom onset and rate of deterioration can vary considerably. In affected infants prognosis is poor, such that without treatment most infants die within the first year of life. To lose a baby in their first year of life to a rare disease causes much regret, guilt, and loneliness to parents, family, and friends. To lose a baby needlessly when there is an effective treatment amplifies this sadness. With so little experience of rare disease in the community, once a baby transfers to their home they are subject to a very uncertain and unyielding diagnostic journey while their symptomology progresses and their health deteriorates. With a rare disease like PD, the best opportunity to diagnose a baby is at birth. PD is not yet included in the current newborn screening (NBS) panel in Australia. Should it be? In late 2018 the Australian Pompe Association applied to the Australian Standing committee on Newborn Screening to have PD included. The application was not upheld. Here we provide an overview of the rationale for NBS, drawing on the scientific literature and perspectives from The Australian Pompe Association, its patients and their families. In doing so, we hope to bring a new voice to this very important debate. View Full-Text
Keywords: Pompe disease; newborn screening; diagnosis; infantile onset Pompe disease; late onset Pompe disease; patient perspective Pompe disease; newborn screening; diagnosis; infantile onset Pompe disease; late onset Pompe disease; patient perspective
Show Figures

Figure 1

MDPI and ACS Style

Saich, R.; Brown, R.; Collicoat, M.; Jenner, C.; Primmer, J.; Clancy, B.; Holland, T.; Krinks, S. Is Newborn Screening the Ultimate Strategy to Reduce Diagnostic Delays in Pompe Disease? The Parent and Patient Perspective. Int. J. Neonatal Screen. 2020, 6, 1.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop